<DOC>
	<DOCNO>NCT01985477</DOCNO>
	<brief_summary>The goal Phase I portion clinical research study find high tolerate dose combination lenalidomide , all-trans retinoic acid ( ATRA ) , dexamethasone give patient relapse refractory multiple myeloma ( MM ) . The goal Phase II portion study learn ATRA give combination lenalidomide alone lenalidomide dexamethasone help control multiple myeloma . In September 2015 , study terminate due slow accrual still Phase I study , additional registration research perform Phase II portion study .</brief_summary>
	<brief_title>Revlimid / All-Trans Retinoic Acid ( ATRA ) / Dexamethasone Relapsed/Refractory Multiple Myeloma</brief_title>
	<detailed_description>Study Groups : If find eligible take part study , assign study group base join study . Up 2 group 3-6 patient participant enrol Phase I portion study , 58 participant enrol Phase II . If enrolled Phase I portion , dose lenalidomide , dexamethasone , ATRA receive depend join study . The first group participant receive low dose level combination . Each new group receive high dose combination group , intolerable side effect see . This continue high tolerable dose combination lenalidomide ATRA find . If enrol Phase II portion , assign 1 2 group base therapy receive begin take part study . - If receive lenalidomide alone , take lenalidomide ATRA ( Group A ) . - If receive lenalidomide dexamethasone start study , take lenalidomide , dexamethasone , ATRA ( Group B ) . Study Drug Administration : Each cycle 28 day . The first part study , call induction , 3 cycle . After maintenance part study . You able continue maintenance long doctor think best interest . Induction : - On Day 1-21 cycle , take lenalidomide mouth 1 time every day . - On Days 1-21 cycle , take ATRA mouth 2 time day . - On Days 1 , 8 , 15 , 22 cycle ( +/- 3 day ) , take dexamethasone mouth . Maintenance : - On Day 1-21 cycle , take lenalidomide mouth 1 time every day . - On Days 1-14 cycle , take ATRA mouth 2 time day . - If Group A , Days 1 , 8 , 15 , 22 cycle ( +/- 3 day ) , take dexamethasone mouth . If dose lenalidomide miss vomit , continue regular schedule drug next dose , miss dose NOT make . Lenalidomide capsule swallow whole , broken , chew open . If take prescribe dose lenalidomide , seek emergency medical care need contact study staff right away Study Visits : Induction Study Visits : On Days 1 , 8 , 15 Cycle 1 : - You physical exam . - Blood ( 3 tablespoon ) drawn routine test . - Urine collect 24 hour check status disease ( Day 1 ) . Between Days 19 21 Cycle 1 , bone marrow aspiration blood ( 1 teaspoon ) drawn measure level certain protein research purpose . On Day 1 Cycles 2-3 : - You physical exam . - Blood ( 3 tablespoon ) draw routine test - Blood ( 1 teaspoon ) drawn measure proteins blood . - Urine collect 24 hour check status disease . If doctor think need , visit may take place often . You may extra visit time study doctor think need care . Maintenance Therapy Study Visits : Once month Maintenance Therapy : - You physical exam . - Blood ( 2 teaspoon ) draw routine test . - Blood ( 1 teaspoon ) drawn measure proteins blood . - Urine collect 24 hour check status disease . - If doctor think need , bone marrow biopsy check status disease . Length Study : You receive 3 cycle study drug induction . You may continue take study drug maintenance long doctor think best interest . You longer able take study drug disease get bad intolerable side effect occur , unable follow study direction . Your participation study end-of-study visit . End-of-Study Visit : If go study reason , end-of-study visit . This usually do 30 day last dose study drug . At visit , follow test procedure perform : - You physical exam . - Blood ( 2-3 teaspoon ) urine ( 24 hour ) collect check status disease . - Blood ( 1 tablespoon ) drawn routine test . - If doctor think need , bone marrow biopsy check status disease . This investigational study . ATRA FDA approve commercially available treat acute promyelocytic leukemia . Lenalidomide FDA approve commercially available treat MM . Dexamethasone FDA approve commercially available treat inflammation allergic condition manage symptoms several type leukemia lymphoma . The combination ATRA , lenalidomide , dexamethasone investigational . Up 70 participant enrol study . All take part MD Anderson .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Tretinoin</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>1 . Understand voluntarily sign informed consent form 2 . Age &gt; /= 18 year time signing informed consent form 3 . Serum creatinine &lt; /= 2.5 mg/dl OR Creatine clearance &gt; 30 ml/min 4 . Eastern Cooperative Oncology Group ( ECOG ) performance status score 0 , 1 , 2 5 . Females childbearing potential ( FCBP ) * must negative serum urine pregnancy test sensitivity least 50 mlU/mL within 1014 day prior within 24 hour start lenalidomide must either commit continued abstinence heterosexual intercourse begin TWO acceptable method birth control , one highly effective method one additional affective method AT THE SAME TIME , least 28 day start take lenalidomide . FCBP must also agree ongoing pregnancy test . Men must agree use latex condom sexual contact female childbearing potential even successful vasectomy . All patient must counsel minimum every 28 day pregnancy precaution risk fetal exposure . 6 . Continuation Inclusion # 5 : *A female childbearing potential sexually mature woman : 1 ) undergone hysterectomy bilateral oophorectomy ; 2 ) naturally postmenopausal least 24 consecutive month ( i.e. , menses time precede 24 consecutive month ) . 7 . Able take prophylactic antiplatelet/anticoagulation , warfarin equivalent agent 8 . Patient able understand comply term condition Lenalidomide Counseling Program . 9 . Phase I Specific Multiple myeloma progress lenalidomide dexamethasone combination therapy dose 25 mg daily lenalidomide 40 mg weekly dexamethasone measurable level myeloma paraprotein serum ( &gt; /= 0.5 g/dl ) , urine ( &gt; /= 0.2 g excrete 24hour collection sample ) , abnormal free light chain ( FLC ) ratio . 10 . Phase I Specific Laboratory test result within range : Absolute neutrophil count &gt; 1000 cells/mm^3 ; Platelet count &gt; 100,000 cells/mm^3 patient &lt; 50 % bone marrow plasma cell platelet count &gt; 50,000 cells/mm^3 patient &gt; 50 % bone marrow nucleate cell plasma cell ; Total bilirubin &lt; /= 2.0 mg/dL ; AST ( SGOT ) ALT ( AGPT ) &lt; 3 x upper limit normal ( ULN ) 11 . Phase II Specific Cohort A : Multiple myeloma progress lenalidomide dexamethasone combination therapy measurable level myeloma paraprotein serum ( &gt; /= 0.5 g/dl ) , urine ( &gt; /= 0.2 g excrete 24hour collection sample ) , involve FLC level 10 mg/dL abnormal free light chain ( FLC ) ratio . Cohort B : Multiple myeloma progress single agent lenalidomide therapy measurable disease define : double Mcomponent 2 consecutive measurement less equal 2 month OR increase serum Mprotein level &gt; /= .5g urine protein 200mg/24 hour , involve FLC level 10 mg/dL ( abnormal FLC ratio ) . 12 . Phase II Specific Laboratory test result within range : Absolute neutrophil count &gt; 1000 cells/mm^3 ; Platelet count &gt; 75,000 cells/mm^3 patient &lt; 50 % bone marrow plasma cell platelet count &gt; 50,000 cells/mm^3 patient &gt; 50 % bone marrow nucleate cell plasma cell ; Total bilirubin &lt; /= 2.0 mg/dL ; AST ( SGOT ) ALT ( AGPT ) &lt; 3 x ULN 1 . Any serious medical condition , psychiatric illness would prevent subject signing informed consent form . 2 . Pregnant breast feeding female . ( Lactating female must agree breast feed take lenalidomide ) . 3 . Use cancer therapy within 14 day prior begin cycle 1 day 1 therapy exception lenalidomide dexamethasone ( radiation therapy allow within 5 day completion radiation therapy ) 4 . Known hypersensitivity lenalidomide ATRA .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Myeloma</keyword>
	<keyword>Multiple myeloma</keyword>
	<keyword>MM</keyword>
	<keyword>Relapsed/Refractory Multiple Myeloma</keyword>
	<keyword>RR MM</keyword>
	<keyword>Lenalidomide</keyword>
	<keyword>CC-5013</keyword>
	<keyword>Revlimid</keyword>
	<keyword>Dexamethasone</keyword>
	<keyword>Decadron</keyword>
	<keyword>All-Trans Retinoic Acid</keyword>
	<keyword>ATRA</keyword>
	<keyword>Tretinoin ( Oral )</keyword>
	<keyword>Vesanoid</keyword>
</DOC>